Novo Nordisk
United States
1217 articles about Novo Nordisk
-
Octagon Therapeutics Enters Inflammation-Focused Research Alliance with Novo Nordisk
9/20/2022
Octagon Therapeutics today announced the initiation of a research collaboration with Novo Nordisk focused on inflammatory disease.
-
Zealand Pharma Announces Global License and Development Agreement with Novo Nordisk for ZEGALOGUE® (dasiglucagon)
9/7/2022
Zealand Pharma A/S announced it has entered into a global license and development agreement with Novo Nordisk A/S to commercialize ZEGALOGUE® for injection.
-
Investigational 2.0mg Semaglutide Dose Promoted for Type 2 Diabetics With Higher A1c ScoreOzempics Continuing to Stand Out as a New Type 2 Diabetes Medication Alternative
9/7/2022
Novo Nordisk introduced Ozempic to the market in 2017, giving Type 2 diabetics a different option when it comes to their injections made for keeping their blood sugar levels down and managing their diabetes effectively.
-
Novo Nordisk has entered into an agreement to acquire Forma Therapeutics for $1.1 billion. Forma’s lead development candidate, etavopivat, is being developed for sickle cell disease.
-
A combination of Novo Nordisk's CagriSema injection for overweight people with type II diabetes resulted in a 15.6% body weight reduction compared to taking the drugs individually.
-
As the world faces one public health crisis after another, it seems that pharmaceutical companies across the board are having trouble keeping up with the ever-growing need for medicines.
-
Sanofi announced positive data for its therapeutic, fitusiran, for treating patients with hemophilia A and B, as well as efanesoctocog alfa therapy for treating hemophilia A.
-
Angion Biomedica Corp. discontinued a Phase II kidney disease trial while Novo Nordisk missed the mark in a NASH study.
-
Versanis Bio's data reveals the results of a pooled analysis, showing that its lead asset, bimagrumab, improves body composition in both diabetic and non-diabetic patients.
-
Initial data from Novo Nordisk's Phase III trial on Sogroya (somapacitan) to treat growth hormone deficiency (GHD) demonstrated safety and efficacy in prepubertal children.
-
Novo Nordisk and Eli Lilly came under legal scrutiny this week, while BMS forked over $11 million to settle claims over anticompetitive tactics.
-
Aslan partners with Johns Hopkins and Duke, Editas joins forces with Immatics, Yumanity (soon to be Kineta, Inc.) teams with Janssen, Serotiny & Janssen Biotech and Ginkgo and Novo Nordisk.
-
The Phase I mechanism of action study, showing that Lilly's injectable Mounjaro (tirzepatide) induces greater weight loss than placebo and Novo Nordisk’s semaglutide in adults with type 2 diabetes.
-
Ginkgo Bioworks and Novo Nordisk to Collaborate on Expression Systems for Pharmaceutical Products
6/7/2022
Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration with Novo Nordisk, a leading global healthcare company, to create novel expression hosts for pharmaceutical products.
-
The results demonstrated that Jardiance reduced the risk of hospitalization for heart failure compared to two other classes of glucose-lowering drugs in adults with type 2 diabetes.
-
The results showed that insulin icodec is as non-inferior to Sanofi’s insulin glargine, Lantus, potentially bringing another major competitor into the insulin space.
-
Researchers continue to explore how to turn deadly venom into life-saving drugs. Several papers on the subject have recently been published and BioSpace is taking a look at them.
-
In addition to lowering of blood sugar, Mounjaro also enabled patients to lower their weight by 15 to 23 pounds. The drug compared well to other diabetes medications including Novo Nordisk's semaglutide.
-
Flagship Pioneering has partnered with Novo Nordisk to build a portfolio of potential treatments for cardiometabolic and rare diseases.
-
The charges come from several in-process research and development projects acquired outside of a business combination.